Feasibility of hippocampus-sparing VMAT for newly diagnosed glioblastoma treated by chemoradiation: pattern of failure analysis

Table 3 Univariate analysis for contralateral hippocampus failure

Variables	cHC failure-free rate^a		P^b	cHC + 1 cm failure-free rate^a		P^b
Variables	6 months (%)	12 months (%)	P^b	6 months (%)	12 months (%)	P^b
All patients	98.7 ± 1.3	97.2 ± 1.9		98.8 ± 1.2	93.4 ± 3.3
MGMT promoter methylation			0.868			0.628
Yes	100.0	100.0		100.0	92.4 ± 5.1
No	97.6 ± 2.4	94.7 ± 3.6		97.8 ± 2.2	94.9 ± 3.5
IDH1 mutation			0.080			0.234
Yes	100.0	100.0		100.0	100.0
No	98.6 ± 1.3	97.1 ± 2.0		98.7 ± 1.3	93.0 ± 3.5
Surgery			0.594			0.790
GTR	97.1 ± 2.9	97.1 ± 2.9		97.1 ± 2.9	92.8 ± 5.0
PR	100.0	100.0		100.0	95.5 ± 4.4
Biopsy	100.0	91.7 ± 8.0		100.0	91.7 ± 8.0
Subventricular zone involvement			0.034			0.113
Yes	97.9 ± 2.1	95.5 ± 3.1		98.0 ± 2.0	91.8 ± 4.8
No	100.0	100.0		100.0	95.7 ± 4.3
Spatial relationship to the subventricular zone [19]			0.196			0.211
Group I	97.1 ± 2.9	93.8 ± 4.2		97.1 ± 2.9	88.3 ± 6.7
Group II	100.0	100.0		100.0	100.0
Group III	100.0	100.0		100.0	100.0
Group IV	100.0	100.0		100.0	75.0 ± 21.7

Abbreviations: cHC contralateral hippocampus, MGMT methylated O6-methylguanine-DNA methyltransferase, IDH1 mutated isocitrate dehydrogenase 1, GTR gross total resection, PR partial resection
^aFailure rates are displayed with standard errors
^bLog-rank test

ISSN: 1748-717X